HP-3060

HP-3060 is a transdermal patch formulation of **emedastine difumarate**, a second-generation antihistamine, developed by **Hisamitsu Pharmaceutical** for the treatment of **allergic rhinitis**. Utilizing Hisamitsu's proprietary transdermal drug delivery system (TDDS) technology, HP-3060 is designed to provide sustained systemic delivery of the active ingredient, potentially offering advantages such as improved patient compliance and more stable plasma concentrations compared to oral or nasal antihistamine formulations. Emedastine acts as a potent and selective **histamine H1 receptor antagonist**, blocking the action of histamine on effector cells to alleviate symptoms like sneezing, rhinorrhea, and nasal congestion. As of recent reports, HP-3060 is in **Phase 3** clinical development in Japan.

Other names

emedastine difumarate patch